Heartburn Medicines May Be The Answer To Covid-19 Infection

Nikki Attkisson | Last Updated : February 12, 2022

The world is currently reeling under the effects of the Omicron variant of the Coronavirus. It erupted way back in 2019 from a Chinese laboratory in Wuhan and has spread into a pandemic. From the very beginning, the authorities have stressed vaccination as the key to reigning in infections.

Heartburn Medicines May Be The Answer To Covid-19 Infection

Apart from vaccinations, another mode of treatment that has been doing the rounds is monoclonal antibody treatment. So, it is quite evident that an arsenal is already ready with the government.

Heartburn Medicines May Be The Answer To Covid-19 Infection

However, from the early days of the pandemic, a massive amount of research work is underway to find out possible protection from other medicines that are already available.

The other mandate that the word is following at present is masking. It is second only to getting vaccinated. It has been noted that social distancing and lockdowns could curb the spread only to a certain extent.

Moreover, countries, including the US have had to face massive losses, due to such mandates and measures. Therefore, ongoing research on various variants seems to be the key to arresting the virus’s spread.

Currently, Omicron is the variant of concern in several states in the US. It has been seen that the Omicron comes with a huge number of mutations that make it difficult to capture by antibodies. Moreover, people who have earlier been infected with Delta have also contracted the Omicron.

At the beginning of the pandemic, another drug that is commonly found was helmed as the possible answer to the virus. It was supposedly inexpensive and could be used to treat the masses. However, very recent studies have shown that the drug is showing mixed results in various individuals.

Famotidine is the active ingredient that is being sold under various brand names. The drug seems to control the symptoms, in mild to moderate infectious states in various specimens in clinical trials.

The active ingredient is Pepcid which showed some number of infections in various individuals. Many of the participants of the trial showed an improvement in symptoms in about 8 days. Many of the participants were also placed under placebo and they showed better signs in 11 days.

Various Infectious diseases experts from the CDC and allied medical bodies seem to be ecstatic over the facts. In the trials, around 80 mg of Famotidine was administered to the participants thrice daily for 14 days. The dosage is quite high, compared to what people take for heartburn.

Going back to the early stages of the virus, China is where the interest in Famotidine seems to have grown from. In 2020, in the initial months, it was observed that poor income families were getting cured faster than wealthy people, after being infected with Coronavirus.

It was also observed that the poor income families were reliant on drugs containing Famotidine to treat heartburn. However, the wealthy individuals were taking other drugs for the same.

The poor seemed to be doing quite well after taking Famotidine. This was quickly picked up by the US and research started on the same. However, recent trials have shown many mixed results.

The trials transferred from the laboratories to hospitalized patients. However, it could not be completed, as the other treatments way back in 2020, came into the picture. The study was stopped in between. However, the drug again came into the picture when the former president of the US took the infection and was hospitalized.

It had seemed to assist the president to get well. However, many months later, the trials again started and showed that Famotidine does not produce the desired results in hospitalized people. Currently, no authority in the medical fraternity can give a possible answer to the future of Famotidine. 

Nikki Attkisson

With over 15 years as a practicing journalist, Nikki Attkisson found herself at Powdersville Post now after working at several other publications. She is an award-winning journalist with an entrepreneurial spirit and worked as a journalist covering technology, innovation, environmental issues, politics, health etc. Nikki Attkisson has also worked on product development, content strategy, and editorial management for numerous media companies. She began her career at local news stations and worked as a reporter in national newspapers.

Sign Up For Our Daily Dose Of Hot News